Multiple Systems Atrophy
- Age-Related Macular Degeneration
- Alzheimer’s Disease
- Amyotrophic Lateral Sclerosis
- Autism Spectrum Disorder
- Chronic Mental Diseases
- Chronic Traumatic Encephalopathy
- Conjunctival Amyloidosis
- Corticobasal Degeneration
- Creutzfeldt–Jakob Disease
- Dementia With Lewy Bodies
- Dentatombral-Pallidoluysian Atrophy
- Desmin-Related Cardiomyopathy
- Dialysis-Related Amyloidosis
- Familial Alzheimer’s Disease
- Familial Amyloidotic Cardiomyopathy
- Familial Amyloidotic Polyneuropathy
- Familial Amyotrophic Lateral Sclerosis
- Familial British Dementia
- Familial Danish Dementia
- Familial Fatal Insomnia
- Familial Mediterranean Fever
- Familial Oculoleptomeningel Amyloidosis
- Familial Parkinson’s Disease
- Finnish Hereditary Systemic Amyloidosis
- Frontotemporal Dementia
- Gerstmann–Sträussler–Scheinker Syndrome
- HIV Infection
- Hereditary Cerebral Amyloid Angiopathy
- Hereditary Non-Neuropathic Systemic Amyloidosis
- Hereditary Renal Amyloidosis
- Huntington’s Disease
- Inclusion Body Myositis
- Insulin-Related Amyloidosis
- Isolated Atrial Amyloidosis
- Medullary Carcinoma Of The Thyroid
- Multiple Systems Atrophy
- Parkinson’s Disease
- Pick’s Disease
- Preeclampsia
- Primary Amyloidosis
- Progressive Supranuclear Palsy
- Prostatic Amyloidosis
- Pure Autonomic Failure
- Senile Systemic Amyloidosis
- Spinal And Bulbar Muscular Atrophy
- Spinal Cord Injury And Traumatic Brain Injury
- Spinocerebellar Ataxia Types 1, 2, 3, 6, 7, And 17
- Systemic (Reactive) Aa Amyloidosis
- Type-2 Diabetes Mellitus
Multiple systems atrophy (MSA) is a neurodegenerative disease in which nerve cells degenerate in particular areas of the brain causing problems with movement, balance, and other autonomic functions of the body, such as bladder control and blood-pressure regulation. In addition, some patients may develop dementia. Some symptoms of MSA overlap with Parkinson’s disease, whereas others are similar to those of ataxia. The prevalence of MSA is estimated at 4.6 per 100,000 people. The mean survival rate after onset of the motor symptoms is 5-8 years and only 20% of patines survive past 12 years. Similarly to Parkinson’s disease, MSA is a synucleinopathy because a major pathological mechanism in MSA is abnormal aggregation of α-synuclein. In MSA, aggregated α-synuclein is deposited primarily in oligodendrocytes, the brain cells that make the myelin sheets. The deposits are called glial cytoplasmic inclusions.